Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic
Antonelli, E;Dal Bello, G;Zucca, M;Girolomoni, G;
2022-01-01
Abstract
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Hansel Clin Experimental Derm 2022.pdf
solo utenti autorizzati
Tipologia:
Documento in Post-print
Licenza:
Accesso ristretto
Dimensione
1.11 MB
Formato
Adobe PDF
|
1.11 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
